rdf:type |
|
lifeskim:mentions |
|
pubmed:issue |
6
|
pubmed:dateCreated |
2000-12-22
|
pubmed:abstractText |
Interleukin-10 (IL-10) exhibits potent anti-inflammatory and immunosuppressive activities in vitro. Recent data indicate that treatment with recombinant human IL-10 (rHuIL-10) Crohn's disease is safe and may induce clinical and endoscopic remission. The present study investigates the in vivo immunomodulatory properties of rHuIL-10 in inflammatory bowel disease (IBD).
|
pubmed:language |
eng
|
pubmed:journal |
|
pubmed:citationSubset |
IM
|
pubmed:chemical |
|
pubmed:status |
MEDLINE
|
pubmed:month |
Nov
|
pubmed:issn |
1081-5589
|
pubmed:author |
|
pubmed:issnType |
Print
|
pubmed:volume |
48
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
449-56
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:11094868-Adult,
pubmed-meshheading:11094868-Double-Blind Method,
pubmed-meshheading:11094868-Female,
pubmed-meshheading:11094868-HLA-DR Antigens,
pubmed-meshheading:11094868-Humans,
pubmed-meshheading:11094868-Immunophenotyping,
pubmed-meshheading:11094868-Immunosuppressive Agents,
pubmed-meshheading:11094868-Inflammatory Bowel Diseases,
pubmed-meshheading:11094868-Intercellular Adhesion Molecule-1,
pubmed-meshheading:11094868-Interleukin-10,
pubmed-meshheading:11094868-Lymphocytes,
pubmed-meshheading:11094868-Male,
pubmed-meshheading:11094868-Middle Aged,
pubmed-meshheading:11094868-Receptors, IgG,
pubmed-meshheading:11094868-Receptors, Interleukin-2,
pubmed-meshheading:11094868-Recombinant Proteins
|
pubmed:year |
2000
|
pubmed:articleTitle |
In vivo effects of recombinant human interleukin-10 on lymphocyte phenotypes and leukocyte activation markers in inflammatory bowel disease.
|
pubmed:affiliation |
Department of Internal Medicine IV, University of Vienna, Austria. clemens.dejaco@akh-wien.ac.at
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|